Skip to main content

Table 2 Changes of pulmonary function test after 3 months combination therapy

From: Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Clinical variable Pre-HSCTa BOS diagnosis 3 months treatment Change of lung function between 3 months treatment and BOS diagnosis P-value (BOS diagnosis vs 3 months treatment)
FVC (L) 3.70 ± 0.86 2.95 ± 0.81 3.18 ± 0.81 0.23 ± 0.43 < .001
FVC (% predicted) 94.14 ± 12.71 73.02 ± 13.23 78.41 ± 13.87 5.39 ± 10.11 < .001
FEV1 (L) 2.94 ± 0.69 1.85 ± 0.57 2.07 ± 0.68 0.22 ± 0.43 < .001
FEV1 (% predicted) 96.00 ± 13.68 56.68 ± 15.48 63.03 ± 19.31 6.36 ± 12.72 < .001
FEV1/FVC (%) 79.86 ± 7.14 63.80 ± 15.34 65.83 ± 16.25 2.04 ± 8.09 .054
RV(L) 1.37 ± 0.38 2.04 ± 0.70 1.84 ± 0.68 −0.20 ± 0.47 .005
RV (% predicted) 79.23 ± 17.64 114.24 ± 36.48 100.41 ± 34.06 −12.90 ± 25.71 .005
TLC (L) 5.11 ± 1.06 5.03 ± 1.13 5.07 ± 1.07 0.04 ± 0.46 .510
TLC (% predicted) 92.93 ± 10.80 89.04 ± 12.31 88.82 ± 11.09 0.45 ± 7.65 .675
RV/TLC (%) 27.02 ± 5.65 40.35 ± 9.79 36.12 ± 10.28 −4.35 ± 7.34 < .001
RV/TLC (% predicted) 83.50 ± 15.77 125.71 ± 33.70 111.22 ± 33.98 −14.06 ± 24.22 < .001
DLCO (% predicted) 62.05 ± 15.51 62.39 ± 17.46 66.32 ± 18.38 4.41 ± 13.80 .027
  1. aFour missing values in Pre-HSCT (N = 57). Data represent the mean ± SD. P-values shown in bold are significant at the 0.05 level. HSCT hematopoietic stem cell transplantation, BOS bronchiolitis obliterans syndrome, FVC forced vital capacity, FEV1 forced expiratory volume in 1s, RV residual volume, TLC total lung capacity, DLCO carbon monoxide diffusion in the lung